<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006080</url>
  </required_header>
  <id_info>
    <org_study_id>2018-002794-21</org_study_id>
    <nct_id>NCT04006080</nct_id>
  </id_info>
  <brief_title>Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis</brief_title>
  <acronym>FAVOUR</acronym>
  <official_title>Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the loss of vedolizumab in stool in patients with
      active ulcerative colitis (UC).

      Patients with moderate-to-severe UC who are commencing induction therapy with vedolizumab
      will be enrolled into a prospective study and stool will be collected for faecal vedolizumab
      measurement at days 1, 4 and 7; and again at weeks 2, 6 and 14. They will also be evaluated
      at three time-points (weeks 2, 6 and 14) for clinical and biochemical UC disease activity as
      well as serum vedolizumab concentrations and anti-vedolizumab antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective

      - To determine whether vedolizumab is present in significant quantities in the stool of
      patients receiving induction therapy with vedolizumab for active UC.

      Secondary objective (s)

        -  To evaluate whether the presence and quantity of vedolizumab in stool can be used to
           predict primary non-response to vedolizumab.

        -  To explore whether a correlation exists between stool vedolizumab concentrations, serum
           vedolizumab concentrations and UC disease activity and extent.

        -  To determine whether there is a correlation between stool and serum vedolizumab levels
           and trafficking of Th1/Th17 effector memory CD4+ T-cells (the key pathogenic subset in
           IBD) to the colon in UC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vedolizumab concentrations in stool</measure>
    <time_frame>Days 1, 4 and 7; and weeks 2, 6 and 14</time_frame>
    <description>Evaluated using an enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UC endoscopic activity</measure>
    <time_frame>Baseline and week 14</time_frame>
    <description>Evaluated using the Mayo Endoscopic Score: Mayo 0 = normal; Mayo 1= mild inflammation; Mayo 2 = moderate inflammation; Mayo 3 = severe inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC endoscopic activity</measure>
    <time_frame>Baseline and week 14</time_frame>
    <description>Evaluated using the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score: Vascular pattern= Normal (0), patchy loss (1), obliterated (2); Bleeding = None (0), mucosal (1), luminal mild (2), luminal moderate (3); Erosions/ulcers = None (0), erosions (1), superfical ulcer (2), deep ulcer (3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical UC disease activity</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
    <description>Evaluated using Patient Reported Outcome 2 (PRO2) Questionnaire: Stool frequency= normal (0), 1-2 more (1), 3-4 more (2), 5 or more stools than normal (3); Rectal bleeding= no blood (0), streaks of blood &lt;50% time (1), obvious blood &gt;50% time (2), blood alone passes (3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vedolizumab serum concentrations</measure>
    <time_frame>Weeks 2, 6 and 14</time_frame>
    <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vedolizumab anti-drug antibody levels</measure>
    <time_frame>Weeks 2, 6 and 14</time_frame>
    <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal calprotectin</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
    <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CRP (mg/L)</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin (g/L) [40-52g/L]</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
    <description>IBD-Control questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical UC disease activity</measure>
    <time_frame>Day 0, weeks 2, 6 and 14</time_frame>
    <description>Evaluated using the Simple Clinical Colitis Activity Index score: Bowel frequency day= 0-3 (0), 4-6 (1), 7-9 (2), &gt;9 (3); Bowel frequency night= 0 (0), 1-3 (1), 4-6 (2); Urgency of defectation= None(0), Hurry (1), immediately (2), incontinence (3); Blood in stool = None (0), trace (1), occasional frank (2), usually frank (3); General well being= very well (0), slightly below par (1), poor (2), very poor (3), terrible (4); Extracolonic features (1 point for each) = arthritis, uveitis, erythema nodosum, pyoderma gangrenosum. Remission SCCAI ≤ 2; Response SCCAI ≤ 5, with a decrease by ≥ 2; Relapse SCCAI ≥ 5 (following a response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC histological activity</measure>
    <time_frame>Day 0 and week 14</time_frame>
    <description>Evaluated using Nancy Histological Index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Vedolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <description>Intravenously administered selective leukocyte adhesion molecule inhibitor</description>
    <arm_group_label>Vedolizumab</arm_group_label>
    <other_name>Entyvio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or over, either male or female

          -  Moderate-to-severe UC, defined as:

             - SCCAI &gt; 5 and, i. A raised fecal calprotectin (&gt; 59 μg/g) or, ii. A raised CRP (&gt; 5
             mg/L) or, iii. Endoscopic disease activity Mayo 2 or above, Evaluated within 6 weeks
             of study enrollment

          -  Commencing vedolizumab treatment

          -  Sufficient English language skills to understand the patient information sheet and
             consent form

        Exclusion Criteria:

          -  Contra-indication to vedolizumab (i.e. known serious or severe hypersensitivity
             reaction to vedolizumab or any of its excipients)

          -  Imminent need for colectomy (i.e. colectomy is being planned)

          -  Previous ileoanal pouch formation

          -  Active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis,
             and opportunistic infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgina Cunningham, MBBS</last_name>
      <phone>07378787000</phone>
      <email>georgina.cunningham@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Irving, MB BChir</last_name>
      <phone>02071882499</phone>
      <email>peter.irving@gstt.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. Epub 2006 Dec 20. Review.</citation>
    <PMID>17258735</PMID>
  </reference>
  <reference>
    <citation>Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9.</citation>
    <PMID>3317057</PMID>
  </reference>
  <reference>
    <citation>Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov;145(5):987-95. doi: 10.1053/j.gastro.2013.07.024. Epub 2013 Jul 25.</citation>
    <PMID>23891974</PMID>
  </reference>
  <reference>
    <citation>Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov;42(10):1200-10. doi: 10.1111/apt.13408. Epub 2015 Sep 21.</citation>
    <PMID>26388424</PMID>
  </reference>
  <reference>
    <citation>Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr;61(4):535-42. doi: 10.1136/gutjnl-2011-300486. Epub 2011 Oct 13.</citation>
    <PMID>21997563</PMID>
  </reference>
  <reference>
    <citation>Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut. 2014 Jul;63(7):1092-102. doi: 10.1136/gutjnl-2013-305600. Epub 2013 Oct 9.</citation>
    <PMID>24107590</PMID>
  </reference>
  <reference>
    <citation>Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Development and validation of the Nancy histological index for UC. Gut. 2017 Jan;66(1):43-49. doi: 10.1136/gutjnl-2015-310187. Epub 2015 Oct 13.</citation>
    <PMID>26464414</PMID>
  </reference>
  <reference>
    <citation>Globig AM, Hennecke N, Martin B, Seidl M, Ruf G, Hasselblatt P, Thimme R, Bengsch B. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis. 2014 Dec;20(12):2321-9. doi: 10.1097/MIB.0000000000000210.</citation>
    <PMID>25248005</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

